Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Sub-industry and Supply-chain Study

Comparative structure study

The largest recorded reporting jurisdiction, Jiangsu, contains 84 records (13.1% of this 643-record cohort). The remaining cohort contains 559 records. The comparison concerns archive composition.

The recorded reporting jurisdiction label Shenzhen accounts for 4.8% here (31/643), compared with 7.9% in the parent set (108/1,373), an absolute gap of 3.0 percentage points.

250/643 companies link to pages with existing source-supported excerpts (38.9% of the cohort). The other 393 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine and medical devices / Complete systems and use-case applications, contains 1,373 records. This cohort contributes 643 (46.8%); 730 records remain after excluding it.

The parent set, Biomedicine, contains 699 records. This cohort contributes 643 (92.0%); 56 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded reporting jurisdiction label Shenzhen covers 77/730 remaining records (10.5%), an absolute gap of 5.7 percentage points from this cohort.

The full reporting jurisdiction distribution has 34 labels; the top 3 contain 200/643 records (31.1%).Other known labels contain 443 records.

For 643 records with known labels, the effective category count is 15.9, versus 34 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 24 others are included in the calculations above.

Record counts do not rank supply capability or economic size.

The largest intersection, Jiangsu × Biomedicine, contains 79 records, or 94.0% of the 84 records carrying the Jiangsu label.

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 51 non-empty cells; the other 43 remain in the analysis.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

125 of this cohort’s 643 records link through existing company-ID mappings to 2026 lists from all jurisdictions (19.4%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

Shared records with Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 643; records in this cohort but outside that set: 0. The intersection/union ratio is 46.8%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 614; records in this cohort but outside that set: 29. The intersection/union ratio is 46.5%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.